Biophytis S.A. (ALBPS.PA)
- Previous Close
0.0025 - Open
0.0026 - Bid --
- Ask --
- Day's Range
0.0024 - 0.0026 - 52 Week Range
0.0022 - 0.0325 - Volume
8,951,692 - Avg. Volume
22,109,989 - Market Cap (intraday)
2.865M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Apr 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.00
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
www.biophytis.comRecent News: ALBPS.PA
Performance Overview: ALBPS.PA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALBPS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALBPS.PA
Valuation Measures
Market Cap
2.64M
Enterprise Value
2.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.78%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.03M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
5.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.66M
Company Insights: ALBPS.PA
ALBPS.PA does not have Company Insights